PET Imaging Agents (FES, FFNP, and FDHT) for Estrogen, Androgen, and Progesterone Receptors to Improve Management of Breast and Prostate Cancers by Functional Imaging

Many breast and prostate cancers are driven by the action of steroid hormones on their cognate receptors in primary tumors and in metastases, and endocrine therapies that inhibit hormone production or block the action of these receptors provide clinical benefit to many but not all of these cancer pa...

Descripción completa

Detalles Bibliográficos
Autor principal: Katzenellenbogen, John A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7465097/
https://www.ncbi.nlm.nih.gov/pubmed/32718075
http://dx.doi.org/10.3390/cancers12082020

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7465097/
https://www.ncbi.nlm.nih.gov/pubmed/32718075
http://dx.doi.org/10.3390/cancers12082020

Ejemplares similares